Skip to content
Log in
Sponsored AI Networking Cookbook: Practical recipes for AI-assisted network automation and development AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
Review

Lipoprotein(a) in Cardiovascular Disease Prevention: Current and Emerging Therapeutic Approaches

Jeffery Osei Josiah Bennett Om Raval Grace Seo Scott D. Eisenberg Rachel Nyenhuis Gabrielle Gershon Samuel Stresemann Sueda Akkaya Anushua Bhattacharya Alexander C. Razavi Anurag Mehta Laurence S. Sperling
Jul 2026 · Current Treatment Options in Cardiovascular Medicine · Vol 28 · 0 citations · 85 references

TL;DR

Observational research and post-hoc analyses suggest that aspirin use may be associated with lower ASCVD risk among individuals with elevated Lp(a), supporting an individualized, shared decision-making approach that considers bleeding risk, overall cardiovascular risk profile, and additional markers of cardiovascular risk.

DOI Semantic Scholar
View source

Similar papers

Review Open access Aug 2026

The role of lipoprotein (a) in premature cardiovascular disease: primed for prevention.

This review examines the role of elevated Lp(a) in premature cardiovascular events, including premature myocardial infarction, stroke, and peripheral arterial disease, and highlights the importance Lp(a) testing may play in secondary prevention, focusing on cascade screening for elevated Lp(a) in relatives of affected...

M. Safarova, Laurence S. Sperling, Anurag Mehta et al. · 0 citations
Review Open access Aug 2026

Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives

Lp(a) may soon shift from a “silent threat” to a precise, actionable target in cardiovascular prevention, according to a review of the current evidence, which highlights gaps in knowledge, and discusses emerging therapeutic strategies.

Michał Miszczak, P. Piwowarczyk, G. Sobieszek et al. · 0 citations
Review Open access Sep 2026

Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention

Novel unapproved therapies, including an antisense oligonucleotide, small interfering RNAs, and an oral small molecule have demonstrated Lp(a) reductions of up to 99% and are being tested in ongoing cardiovascular outcomes trials to determine whether pharmacologic Lp(a) lowering translates into reduced cardiovascular e...

Yakubu Bene-Alhasan, V. Nambi, Layla A. Abushamat et al. · 0 citations
#gene editing Open access Sep 2026

Lipoprotein(a) as an independent cardiovascular risk factor

Emerging evidence links Lp(a) to atrial fi brillation, broadening its clinical relevance and integrating Lp(a) testing into risk assessment and preparing for targeted therapies are critical steps in modern cardiovas-cular prevention.

L. Kopaleishvili, T. Chkhaidze, S. Ungiadze et al. · 0 citations
Review Aug 2026

Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.

Current evidence supports strong biological efficacy, but definitive proof of clinical benefit awaits ongoing randomized cardiovascular outcomes trials, including Lp(a)HORIZON (pelacarsen), OCEAN(a)-Outcomes (olpasiran) and ACCLAIM-Lp(a) (lepodisiran).

José Pablo Miramontes González · 0 citations
Review Open access Aug 2026

Lipoprotein(a) in cardiovascular disease: pathophysiology, residual risk, and emerging therapeutic strategies

This narrative review summarizes the molecular biology, genetics, epidemiology, pathophysiological mechanisms, and clinical relevance of Lp(a), and critically examines current and emerging therapeutic strategies aimed at reducing Lp(a)-mediated cardiovascular risk.

L. Granata, Simona Giubilato, Francesca Campanella et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.